DE69209969T2 - Wasserlösliche Camptothecinderivate - Google Patents

Wasserlösliche Camptothecinderivate

Info

Publication number
DE69209969T2
DE69209969T2 DE69209969T DE69209969T DE69209969T2 DE 69209969 T2 DE69209969 T2 DE 69209969T2 DE 69209969 T DE69209969 T DE 69209969T DE 69209969 T DE69209969 T DE 69209969T DE 69209969 T2 DE69209969 T2 DE 69209969T2
Authority
DE
Germany
Prior art keywords
water soluble
camptothecin derivatives
soluble camptothecin
derivatives
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69209969T
Other languages
English (en)
Other versions
DE69209969D1 (de
Inventor
Michael Joseph Luzzio
Jeffrey M Besterman
Michael G Evans
Peter Leslie Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of DE69209969D1 publication Critical patent/DE69209969D1/de
Application granted granted Critical
Publication of DE69209969T2 publication Critical patent/DE69209969T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
DE69209969T 1991-10-29 1992-10-23 Wasserlösliche Camptothecinderivate Expired - Fee Related DE69209969T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78427591A 1991-10-29 1991-10-29
US82672992A 1992-01-28 1992-01-28

Publications (2)

Publication Number Publication Date
DE69209969D1 DE69209969D1 (de) 1996-05-23
DE69209969T2 true DE69209969T2 (de) 1996-09-12

Family

ID=27120258

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69209969T Expired - Fee Related DE69209969T2 (de) 1991-10-29 1992-10-23 Wasserlösliche Camptothecinderivate

Country Status (25)

Country Link
EP (1) EP0540099B1 (de)
JP (2) JP3020760B2 (de)
KR (1) KR100246154B1 (de)
CN (1) CN1072683A (de)
AP (1) AP306A (de)
AT (1) ATE136898T1 (de)
AU (1) AU657007B2 (de)
CA (1) CA2081580A1 (de)
CZ (1) CZ284023B6 (de)
DE (1) DE69209969T2 (de)
DK (1) DK0540099T3 (de)
ES (1) ES2086643T3 (de)
FI (3) FI104373B (de)
GR (1) GR3020120T3 (de)
HU (2) HU217970B (de)
IL (1) IL103571A (de)
IS (1) IS1708B (de)
MX (1) MX9206211A (de)
MY (1) MY108261A (de)
NO (1) NO302073B1 (de)
NZ (1) NZ244914A (de)
OA (1) OA09767A (de)
RU (1) RU2119921C1 (de)
SK (1) SK279298B6 (de)
TW (1) TW221994B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
DE69435084T2 (de) * 1993-01-15 2009-03-19 The Stehlin Foundation For Cancer Research, Houston Die Verwendung von wasserunlöslichem S-Camptothecin mit geschlossenem Lactonring für die Herstellung eines Medikamentes zur Behandlung von Darmkrebs
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
JPH08509742A (ja) * 1993-05-03 1996-10-15 スミスクライン・ビーチャム・コーポレイション 置換メチレンジオキシ［３’，４’：６，７］インドリジノ［１，２−ｂ］キノリノン
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
IT1269862B (it) * 1994-05-30 1997-04-15 Indena Spa Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
KR960029336A (ko) 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
ATE275132T1 (de) * 1995-06-27 2004-09-15 Takeda Chemical Industries Ltd 4-acylamino(halogen)alkyl-chinolin derivate, deren herstellung und deren verwendung als melatonin-agonisten
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
SG88737A1 (en) 1996-10-30 2002-05-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
CA2401191C (en) 2000-02-28 2006-05-02 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
NZ524855A (en) 2000-10-27 2004-10-29 Aventis Pharma S A combination comprising camptothecin and a stilbene derivative preferably combrestatin for the treatment of cancer
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
WO2006069344A2 (en) 2004-12-22 2006-06-29 Rutgers, The State University Of New Jersey Controlled release hydrogels
CA2658015A1 (en) 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
CN101407524B (zh) * 2007-10-09 2012-07-18 江苏先声药物研究有限公司 噁嗪骈喜树碱衍生物及其制备方法和用途
CN100592871C (zh) * 2008-03-14 2010-03-03 浙江林学院 一种杀虫剂组合物及其加工方法
ES2373172B1 (es) * 2010-07-16 2012-12-10 Consejo Superior De Investigaciones Científicas (Csic) Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales.
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
WO2012096832A2 (en) * 2011-01-12 2012-07-19 Crystal Biopharmaceutical Llc Hdac inhibiting derivatives of camptothecin
US20190343828A1 (en) * 2018-04-06 2019-11-14 Seattle Genetics, Inc. Camptothecin peptide conjugates
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
AU2022330892A1 (en) * 2021-08-19 2024-03-21 Simcere Zaiming Pharmaceutical Co., Ltd. Camptothecin derivative, and pharmaceutical composition and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
JPH05222048A (ja) 1993-08-31
AP9200439A0 (en) 1992-10-31
SK323792A3 (en) 1998-09-09
CZ323792A3 (en) 1993-10-13
AU2738592A (en) 1993-05-06
CZ284023B6 (cs) 1998-07-15
OA09767A (en) 1993-11-30
MX9206211A (es) 1993-05-01
JP3020760B2 (ja) 2000-03-15
AP306A (en) 1994-01-28
SK279298B6 (sk) 1998-09-09
RU2119921C1 (ru) 1998-10-10
ATE136898T1 (de) 1996-05-15
FI924878A (fi) 1993-04-30
HU217970B (hu) 2000-05-28
AU657007B2 (en) 1995-02-23
FI982185A0 (fi) 1998-10-08
HU211349A9 (en) 1995-11-28
FI20021090A (fi) 2002-06-07
MY108261A (en) 1996-09-30
JP2000109475A (ja) 2000-04-18
NO924158D0 (no) 1992-10-28
FI104373B (fi) 2000-01-14
DK0540099T3 (da) 1996-06-17
FI982185A (fi) 1998-10-08
IS1708B (is) 1998-12-16
IS3936A (is) 1993-04-30
JP3229298B2 (ja) 2001-11-19
ES2086643T3 (es) 1996-07-01
TW221994B (de) 1994-04-01
DE69209969D1 (de) 1996-05-23
CN1072683A (zh) 1993-06-02
HU9203384D0 (en) 1993-01-28
NZ244914A (en) 1995-01-27
HUT65719A (en) 1994-07-28
EP0540099B1 (de) 1996-04-17
NO924158L (no) 1993-04-30
GR3020120T3 (en) 1996-08-31
CA2081580A1 (en) 1993-04-30
IL103571A (en) 1998-01-04
IL103571A0 (en) 1993-03-15
NO302073B1 (no) 1998-01-19
KR100246154B1 (ko) 2000-04-01
FI924878A0 (fi) 1992-10-28
EP0540099A1 (de) 1993-05-05

Similar Documents

Publication Publication Date Title
DE69209969T2 (de) Wasserlösliche Camptothecinderivate
MX9100832A (es) Derivados de taxol solubles en agua
ATE154564T1 (de) Wasserlösliche verpackung
ATE158775T1 (de) Wasserlösliche verpackung
DE69208877D1 (de) Chinuclidinderivate
NO922182D0 (no) Krystallinske oksatiolan-derivater
DE69119329T2 (de) Actinonin-Derivate
FI925523A (fi) Hydroxi- och alkoxipyridinderivat
DE69125099T2 (de) Indolderivate
FI925763A (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
ATE144765T1 (de) Hiv-hemmende benzenacetamidderivate
DE69130255T2 (de) Oxadolderivate
DK0472733T3 (da) Phenantrenderivater
DE69119323T2 (de) Fluoräthylcamptothecinderivate
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
DE69211197D1 (de) 1-Hydroxyvitamin D-Derivate
NO920836D0 (no) Vannopploeselige bis-dioksopiperazinderivater
KR930702353A (ko) 2- 카르바페넴 유도체
ZA928324B (en) Water soluble camptothecin derivatives.
DE69227554T2 (de) Indolinospirobenzopyran-derivate
ZA938385B (en) Water soluble camptothecin derivatives
DK81588D0 (da) Gametocide n-phosphonomethylglycinderivater
BR1100452A (pt) Derivados do bifenilmetilimidazol
DK80790D0 (da) Thien-triazol-diazepin-derivater
NO914936D0 (no) Vannopploeselig polymer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GILEAD SCIENCES, INC., (N.D.GES.D. STAATES DELAWAR

8327 Change in the person/name/address of the patent owner

Owner name: OSI PHARMACEUTICALS, INC., MELVILLE, N.Y., US

8339 Ceased/non-payment of the annual fee